The colon is a site where both local and systemic delivery of drugs can take place. Local delivery allows topical treatment of inflammatory bowel disease. However, treatment can be made effective if the drugs can be targeted directly into the colon, thereby reducing the systemic side effects. This review mainly describes the primary approaches for CDDS (Colon Specific Drug Delivery) namely prodrugs, pH and time dependent systems, and microbially triggered systems, which achieved limited success and had limitations as compared with newer CDDS namely pressure controlled colonic delivery capsules. Oral administration of different dosage forms is the most commonly used method due to flexibility in design of dosage form and high patient acceptance, but the gastrointestinal tract presents several formidable barriers to drug delivery. In oral colon-specific drug delivery system, colon has a large amount of lymphoma tissue (facilitates direct absorption in to the blood), negligible brush boarder membrane activity, and much less pancreatic enzymatic activity as compared with the small intestine. Colon-specific drug delivery has gained increased importance not just for the delivery of the drugs for treatment of local diseases associated with the colon but also for its potential for the delivery of proteins and therapeutic peptides. Different approaches are designed based on prodrug formulation, pH-sensitivity, time-dependency (lag time), microbial degradation and osmotic pressure etc to formulate the different dosage forms like tablets, capsules, multiparticulates, microspheres, liposomes for colon targeting. The delivery of drugs to the colon has a number of therapeutic implications in the field of drug delivery. In the recent times, the colon specific delivery systems are also gaining importance not only for local drug delivery of drugs but also for the systemic delivery of protein and peptide drugs. This review updated the research on different approaches formulation and evaluation of colon-specific drug delivery.
Introduction
Now a day, various routes of administration have been explored for the effective delivery of the drug. The oral route is considered to be most convenient for the administration of drugs to patients [1] . Oral delivery of drugs in the colon is valuable in the treatment of diseases of colon (colon cancer, ulcerative colitis, crohn's disease and inflammatory bowel disease) whereby high local concentration can be achieved while minimizing side effects. The colon is attracting interest as a site where poorly absorbed drug molecule may have an improved bioavailability. Additionally, the colon has a long retention time and appears highly responsible to agents that enhance the absorption of poorly absorbed drugs. The simplest method for targeting of drugs to the colon is to obtain slower release rates or longer release periods by the application of thicker layers of conventional enteric coating or extremely slow releasing matrices [2] . Further, drug targeting to colon would prove useful where intestinal delayed drug absorption is desired from therapeutic point of view in the treatment of diseases that have peak symptoms in the early morning such as nocturnal asthma, angina or arthritis [3] . The colon specific drug delivery system (CDDS) should allow drug release only in the colon. The colon is believed to be a suitable site for absorption of peptides and protein drugs for following reasons:
Modified Approaches for Colon Specific Drug Delivery

I.
Less diversity and intensity of digestive enzymes.
II.
Comparatively proteolytic activity of colon mucosa is much less than that observed in the small intestine, thus CDDS protects peptide drugs from hydrolysis and enzymatic degradation in the duodenum and jejunum and eventually releases drugs in the ileum or colon which leads to greater systemic bioavailability.
III.
The colon has along residence time (upto 5 days) and is highly responsive toabsorption enhancers.
Anatomic and Physiological
Consideration [5] The lower gastrointestinal tract includes most of the large intestine and small intestine all of the according to some sources, it also includes the anus. Bowel or intestine, Small intestine, which has three parts:
Duodenum
Here the digestive juices from pancreas (digestive enzymes) and gallbladder (bile) mix together. The digestive enzymes break down proteins and bile emulsifies fats into micelles. Duodenum contains Brunner's glands which produce bicarbonate and pancreatic juice contains bicarbonate to neutralize hydrochloric acid of stomach
Jejunum
It is the midsection of the intestine, connecting duodenum to ileum. Contain plicae circulars, and villi to increase surface area.
Ileum
It has villi, where all soluble molecules are absorbed into the blood (capillaries and lacteals).
Large intestine, which has three parts:
Caecum (the vermiform appendix is attached to the caecum).
Colon (ascending colon, transverse colon, descending colon and sigmoid flexure). The main function of colon is to absorb water, but it also contains Available online on www.ijpbr.in 69 bacteria that produce beneficial vitamins like Vitamin K.
Rectum
Anus:It is the end part of gastrointestinal tract and its pH is about7. 
Advantages of Colonic Drug Delivery System
• Chronic colitis, namely ulcerative colitis, and Crohn's disease are currently treated with glucocorticoids, and other antiinflammatory agents.
• Administrationof glucocorticoids namely dexamethasone and methyl prednisolone by oral and intravenous routes produce systemic side effects including adenosuppression,immunosuppre ssion, cushinoid symptoms, and bone resorption. Thus selective delivery of drugs to the colon could not only lower the required dose but also reduce the systemic side effects caused by high doses.
• Drugs are directly available at the targeted site.
• Decreased side effect.
• Improved drug utilization.
• Comparatively lesser amount of required dose [8, 9] .
Disadvantages of Colonic
Drug Delivery System
• One challenge in the development of colon-specific drug delivery systems is to establish an appropriate dissolution testing method to evaluate the designed system invitro.
• As a site for drug delivery, the colon offers a near neutral pH, reduced digestive enzymatic activity, a long transit time and increased responsiveness to absorption enhancers; however, the targeting of drugs to the colon is very complicated.
• In addition, the stability of the drug is also a concern and must be taken into consideration while designing the delivery system. The drug may potentially bind in a nonspecific way to dietary residues, intestinal secretions, mucus or faecal matter.
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• The resident microflora could also affect colonic performance via metabolic degradation of the drug. Lower surface area and relative 'tightness' of the tight junctions in the colon can also restrict drug transport across the mucosa and into the systemic circulation [10] . 
Applications of Colonic
Modified Approaches of Colon
Drug Delivery System Different modified approaches are in use for development of colon drug delivery system, Newer approaches are aimed at the use of polymers as drug carriers for drug delivery to the colon. Both synthetic as well as naturally occurring polymers have been used for this purpose. some are discussed here.
I. Prodrug Approach A prodrug is pharmacologically inactive derivative of a parent drug molecule that requires spontaneous enzymatic transformation in vivo to release the active drug [12] . In this method the prodrugs are designed to undergo minimum absorption and hydrolysis in the upper GIT and undergo enzymatic hydrolysis in the colon, there by releasing the active drug moiety from the carrier [13, 14] . Different types of conjugates were used to prepare 5-ASA prodrugs which are succeed in releasing the 5-ASA in colonic region. They are biodegradable poly (ether-ester) azo polymers, azolinked polymeric prodrugs, acrylic type
Available online on www.ijpbr.in 71 polymeric prodrugs and cyclodextrin prodrugs [15] . Sub synthetic polymers have been used to form polymeric prodrug with azo linkage between the polymer and drug moiety [16] . These have been evaluated for CDDS. Various azo polymers have also been evaluated as coating materials over drug cores. These have been found to be similarly susceptible to cleavage by the azo reducatase in the large bowel.
Coating of peptide capsules with polymers cross linked with azo aromatic group has been found to protect the drug from digestion in the stomach and small intestine. In the colon, the azo bonds are reduced and the drug is released [17] .
II. Glycoside Conjugates
Steroid glycosides and the unique glycosidase activity of the colonic microflora form the basis of a new colon targeted drug delivery system. Drug glycosides are hydrophilic and thus poorly absorbed from the small intestine.
Once such a glycoside reaches the colon it can be cleaved by bacterial glycosidases releasing the free drug to be absorbed by the colonic mucosa [18, 19] . 
III. Cyclodextrin Conjugates
Cyclodextrins (CyDs) are cyclic oligosaccharides consisted of six to eight glucose units through α −1,4 glucosidic bonds and have been utilized to improve certain properties of drugs such as solubility, stability and bioavailability. The interior of these molecules is relatively lipophilic and the exterior relatively hydrophilic, they tend to form inclusion complexes with various drug molecules [20, 21] . They are known to be barely capable of being hydrolyzed and only slightly absorbed in passage through the stomach and small intestine; however, they are fermented by colonic microflora into small saccharides and thusabsorbed in the large intestine [22] [23] .
IV. pH Dependent Approaches
This approach utilizes the existence of the pH gradient in the GIT that increases progressively from the stomach (pH 1.5-3.5) and small intestine (pH 5.5-6.8) to the colon (6.4-7.0). The most commonly used pH-dependent polymers are derivatives of acrylic acid and cellulose. By combining the knowledge of polymers and their solubility at different pH environments, delivery systems have been designed to deliver drugs at the targetsite [24] . Pre-sensitive enteric coatings have been used routing to deliver drugs to small intenstine. These polymer coatings are insensitive to the acidic conditions of stomach yet dissolve at the higher pH environment of small intestine. This pH differential principle has also been for dissolution that is higher than those used in conventional enteric coating applications. Most commonly copolymers of methacrylic acid and methyl methacrylate that dissolve at pH 5 to pH 7 have been investigated. This approach 
V. Time Dependent Approaches
The time dependent approach is also known as pulsatile release, delayed, or sigmoidal release system. In this approach, drug release from the system occurs after a pre-determined lag time which corresponds to time for the transit from mouth to colon. The lag time depends upon the size of the dosage form and gastric motility associated with the pathological condition of the individual. In general, the timedependent formulation for colonic delivery contains a pH-dependent coating component because the transit of a formulation in the GI tract is largely influenced by the gastric emptying time. This coating is also used to prevent rapid swelling and disintegration in the upper GI tract since other controlled-release components based on the mechanism of swelling, osmosis or a combination of the two are often included in the timedependent release formulations amount. Colon targeting could be achieved by incorporating a lag time into formulation equivalent to the mouth to colon transit time. A nominal lag time of five hours is usually considered sufficient to achieve colon targeting. In this method the solid dosage form coated with different sets of polymers and the thickness of the outer layer determines the time required disperse in aqueous environment [25] .
VI. Microflora Activated System
The basic principle involved in this method is degradation of polymers coated on the drug delivery system by microflora present in colon and there by release of drug load in colonic region because the bioenvironmental inside the human GIT is characterized by presence of complex microflora especially the colon is rich in microorganisms. In this method drugs and/or dosage forms are coated with the biodegradable polymers. The polymers degrade due to influence of colonic microorganisms. When the dosage form passes through the GIT, it remains intact in the stomach and small intestine where very little microbial degradable activity is present which is insufficient for cleavage of the polymer coating. The use of GI microflora as a mechanism of drug release in the colonic region has been of great interest to researchers in recent times. The majority of bacteria are present in the distal gut although they are distributed throughout the GI tract Endogenous and exogenous substrates, such as carbohydrates and proteins, escape digestion in the upper GI tract but are metabolized by the enzymes secreted by colonic bacteria . Sulphasalazine, a prodrug consisting of the active ingredient mesalazine, was the first bacteria-sensitive delivery system designed to deliver the drug to the colon [26] [27] .
VII.
Pressure Dependent Delivery G.I. pressure has also been utilized drug release in distal gut this pressure which is generated via muscular contraction of gut wall for gtinding and proposition of intestinal contents, various in intensity and duration through the g.i. tract, with the colon considered to have a higher internal pressure due to colon. Capsule shells fabricated from water insoluble polymer entry cellulose have been used for this purpose. The system can be modified to withstand and rupture at different pressures by changing the size of capsule and thickness of capsule enzymes that are capable of metabolizing endogenous and exogenous substrates such as carbohydrates, proteins that escape digestion in upper g.i. tract. Therefore materials that are recalcitrant to the conditions of stomach and small intensive yet suspicious to degradation by bacterial enzymes within colon can be utilized as carriers for drug delivery to colon. This principle has been exploited commercially to deliver 5 aminosalicyclic acid to the colon by way of a prodrug career [28] . The prodrug sulphasalazine consists of two separate moieties, 5-aminosalcylic acid, linked by as azo-bond. The prodrug posses through the upper gut in tract, but once in colon the azo-bond is cleaved by the host bacteria, liberating the carrier molecule sulphapyridine and pharmacological active agent 5-aminosalicyclic acid [29] .
Novel Drug Delivery System for Colon Drug Delivery System
Now a days the basic CDDS approaches are applied to formulate novel drug delivery systems like Multiparticulate systems, Microspheres, Liposomes, Microencapsulated particles etc.
I.
Multiparticulate Systems Multiparticulates (pellets, non-perils etc.) are used as drug carriers in pHsensitive, time-dependent and microbial control systems for colon targeting. Multiparticulate systems have several advantages in comparison to the conventional single unit for controlled release technology, such as more predictable gastric emptying and fewer localized adverse effect than those of single unit table. A multiparticulate dosage from was prepared to deliver active molecules to colonic region, which combines pH dependent and controlled drug release properties [30] .
II. Microspheres of Anti-Cancer Drugs
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Cross-linked guar gum microspheres containing methotrexate were prepared and characterized for local release of drug in the colon for efficient treatment of colorectal cancer. In this method glutaraldehyde was used as a crosslinking agent and guar gum microspheres [31] .
III.
Novel Colon Targeted Delivery System (CODESTM) CODESTM is a unique CDDS technology that was designed to avoid the inherent problems associated with pH or time dependent systems [32] . CODESTM is a combined approach of pH dependent and microbial triggered CDDS. It has been developed by utilizing a unique mechanism involving lactulose, which acts as a trigger for site specific drug release in the colon. The system consists of a traditional tablet core containing lactulose which is over coated with and acid soluble material, Eudragit E and then subsequently over coated with an enteric material, Eudragit L. The premise of the technology is that the enteric coating protects the tablet while it is located in the stomach and then dissolves quickly following gastric emptying. The acid soluble material coating then protects the preparation as it passes through the alkaline pH of the small intestine. Once the tablet arrives in the colon, the bacteria enzymatically degrade the polysaccharide (lactulose) into organic acid. This lowers the pH surrounding the system sufficient to affect the dissolution of the acid soluble coating and subsequent drug release [33] . The OROS-CT (Alza Corporation) can be used to target the drug locally to the colon for the treatment of disease or to achieve systemic absorption that is otherwise unattainable. The OROS-CT system can be a single osmotic unit or may incorporate as many as 5-6 pushpull units, each 4 mm in diameter, encapsulated within a hard gelatin capsule each bilayer push pull unit contains an osmotic push layer and a drug layer, both surrounded by a semi permeable membrane. An orifice is drilled through the membrane next to the drug layer. Immediately after the OROS-CT is swallowed, the gelatin capsule containing the push-pull units dissolves. Because of its drug-impermeable enteric coating, each push-pull unit is prevented from absorbing water in the acidic aqueous environment of the stomach, and hence no drug is delivered. As the unit enters the small intestine, the coating dissolves in this higher pH environment (pH >7) water enters the unit causing the osmotic push compartment to swell and concomitantly creates a flow able gel in the drug compartment [34] . 
Evaluation of Colonic Delivery System
Preclinical Evaluation and Animal Models The drug release in the colonic region from different CDDS is evaluated by different methods of in vitro and in vivo release studies, which show the success rate of different designs of colon drug delivery systems. Depending upon the method of preparation different evaluation methods are proposed. A successful colon specific drug delivery system is one of that remains intact in the physiological environment of stomach and small intestine but releases the drug in the colon. In-vitro Evaluation Different in vitro methods are used to evaluate the colonic drug delivery systems. In in-vitro studies the ability of the coats/carriers to remain intact in the physiological environment of the stomach & small intestine is assessed by drug release studies in 0.1N HCl for two hours (mean gastric emptying time) and in pH 7.4 phosphate buffer for three hours (mean small intestine transit time) using USP dissolution apparatus. In case of micro flora activated system dosage form, the release rate of drug is tested in vitro by incubating in a buffer medium in the presence of either enzymes (e.g. pectinase, dextranase) or rat/guinea pig/ rabbit caecal contents. The amount of drug released at different time intervals during the incubation is estimated to find out the degradation of the carrier under study.
In-vivo Evaluation
In vivo studies are usually conducted to evaluate the site specificity of drug release and to obtain relevant pharmacokinetic information of the delivery system. Although animal models have obvious advantages in assessing colon specific drug delivery systems, human subjects are increasingly utilized for evaluation of this type of delivery systems. The preferable animals to evaluate CDDS are rats, guinea pigs and dogs [35] [36] [37] . 
Drug Delivery Index
High-Frequency Capsule
This technique is being used to check absorption properties of drug in colon. The relative bioavailability of colonic drug delivery systems can be evaluated by high-frequency capsule [41] . The principle is schematically presented in Figure 7 . 
Conclusion
The colonic region of the GIT has become an increasingly important site for drug delivery and absorption. Colon drug delivery provides therapeutic benefits to patients in terms of both local and systemic treatment. Colon specificity is more likely to be achieved with systems that utilize natural materials that are degraded by colonic bacterial enzymes. are in use to understand and achieve the desired goal of targeting the delivery to a specific organ, the colon. All the available approaches have their own limitations and advantages and extensive research is being focused on these to improve further. Time-dependant systems are not a very practical solution due to variable GI tract transit times but may have a potential role in diseases that are subject to circadian rhythm. On the other hand, pressure-controlled systems hold some promise but currently little is known about the luminal pressures of different regions of GI tract and at present the commercial manufacturing methods have some unresolved issues to be addressed. The only system available as of today is based on pH but these systems can possibly deliver the drug at the duodenum or may not deliver the drug at all. Further research is on-going in different labs and it is quite likely that a day is not far off when new, improved polymers will replace the existing available polymers with improved performance.
